GLP-1s opened the door — metabolic health as treatable. Rapamycin, senolytics, regenerative medicine on deck. 5-10y arc to "aging as treatable."
Early · 2021-
early
accelerating
peak
declining
§ The wedge — what we think vs consensus
Pending author input.
Contrarian read not yet authored for this shift. The wedge section will name the consensus position, our differing read, and the structural reason for the divergence.
§ Thesis
What's actually shifting.
GLP-1 receptor agonists (Ozempic, Mounjaro, Wegovy) opened the public and regulatory imagination to 'metabolic health as a treatable disease state' — the gateway thesis for longevity biology. The 2020s is the validation phase: rapamycin trials, senolytic clinical readouts, NAD+ pathway modulators, and the broader translation of decades of academic geroscience research into approved therapeutics. Structural enablers: AI-driven biomarker discovery, GLP-1 commercial validation making investor capital flow, demographic urgency (population decline thesis). The shift is the slow extension of healthspan from biological inevitability to clinical target.
§ Stage history
How it got here.
1990s-2010s
pre-shift
Geroscience academic research (mTOR, sirtuins, autophagy, senescence). Mostly niche.
2017-2020
pre-shift
First rapamycin trials in dogs (Dog Aging Project). Pets-to-humans translation pathway emerges.
2021
early
Ozempic / Wegovy approvals. Metabolic health enters mainstream awareness.
2023-2024
early
Rapamycin off-label use at scale. Senolytic trials advance. Altos Labs / NewLimit / Retro Bio funded at multi-billion levels.
2025
early
First major senolytic Phase 3 readouts; rapamycin formal aging trials begin.
§ Asymmetric positions — by category
Where the shift creates differential exposure.
Beneficiaries
GLP-1 manufacturers and supply chain (Novo Nordisk, Eli Lilly, peptide CDMOs)
Treatment-of-disease franchises in metabolic, cardiovascular, oncology where prevention competes
Sugar / processed-food industry (already pivoting; long arc)
Junior-pharma in symptomatic-treatment categories
Health-insurance models that don't price prevention
§ Named positions — specific entities
Where the categorical reads land in particular names.
Specific named positions not yet authored. This section will carry tickers / companies / asset-class names with thesis, risk, and sizing notes — the difference between a category read and a position read.
§ Signal tracking
What would tell you the shift is accelerating — or stalling.
Watch for (acceleration)
First Phase 3 senolytic readout in humans
Rapamycin formal aging-indication approval (or major academic trial outcome)
AI-driven longevity drug discovery first major hit
Insurance reimbursement for biological-age testing
Anti-watch-for (stalling / reversal)
Major safety event in chronic-use rapamycin or GLP-1 cohorts
Public-health backlash to "anti-aging" framing
Regulatory pushback on aging-as-indication trials
Capital-flight from preclinical longevity startups (Altos cool-down)
§ Watch metrics — quantitative
Specific thresholds with current values.
Quantitative watch metrics not yet authored. This section will carry specific named metrics with their threshold levels and current values — the at-a-glance dashboard that turns a description into a tracker.
Key differenceModern medicine emerged 1850-1900 as part of broader industrial-era productivity. Longevity biology is comparable in scope but inverts the model — DELAY aging rather than CURE disease. Different regulatory paradigm; different consumer expectation.
§ Related Lab findings
Where the mechanism is rigorously tested.
No Lab finding has been authored on this shift yet. The shift is tracked here as macro frame; rigorous mechanism testing comes when a finding is registered against the corpus.
§ Cross-shift interactions
Where this shift compounds or conflicts with another.
Epigenetic reprogramming and telomere management are CRISPR-stack interventions; the two shifts converge in regenerative-medicine applications.
§ Track record
Prior calls + outcomes for this shift.
No prior calls logged for this shift yet. The track record builds over time as predictions resolve. It’s the credibility ledger — visible past calls and their outcomes, same way the Lab corpus tracks pre-registered predictions.